TCGA-C8-A12M-01A-11R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.310
- MYC_TARGETS_V1+0.280
- PROTEIN_SECRETION+0.270
- TGF_BETA_SIGNALING+0.180
- DNA_REPAIR+0.140
- WNT_BETA_CATENIN_SIGNALING+0.130
- ANDROGEN_RESPONSE+0.120
- UV_RESPONSE_DN+0.100
- G2M_CHECKPOINT+0.070
- ESTROGEN_RESPONSE_EARLY+0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- INTERFERON_ALPHA_RESPONSE-0.430
- INFLAMMATORY_RESPONSE-0.410
- INTERFERON_GAMMA_RESPONSE-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- IL6_JAK_STAT3_SIGNALING-0.330
- ALLOGRAFT_REJECTION-0.310
- CHOLESTEROL_HOMEOSTASIS-0.290
- APOPTOSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3311 | Med | Medulloblastoma | 0.874 |
| 2 | ERR2598236 | fetal | fetal | 0.869 |
| 3 | TCGA-A7-A3IZ-01A-11R-A213-07 | — | B | 0.865 |
| 4 | TCGA-A7-A0DC-01A-11R-A00Z-07 | — | D | 0.865 |
| 5 | TCGA-E2-A15R-01A-11R-A115-07 | — | B | 0.862 |
| 6 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.856 |
| 7 | MDT-AP-3325 | Med | Medulloblastoma | 0.856 |
| 8 | SRR650200 | — | — | 0.853 |
| 9 | MDT-AP-3021 | Med | Medulloblastoma | 0.853 |
| 10 | SRR662871 | GTEX | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.010 | Inavolisib | — uncovered |